Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S10.04
P/E—
Fwd P/E22.65
PEG1.62
52W— – —
RSI—
Target$554.91 (+14.8%)
Beta0.29
Div—
Loading chart…
RSI (14)
Loading patterns…
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 52
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
4Bullish
0Bearish
0Neutral
▲ Double Bottom — Two lows ~$418.76 — bullish reversal confirmed
▲ Inv. Head & Shoulders — Inv. H&S neckline ~$452.25 broken — major bullish reversal
▲ Double Bottom — Two lows ~$419.14 — bullish reversal confirmed
▲ Bull Flag — Breakout after +13% pole — bullish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
50%
4/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$554.91
+14.8% upside
Low $350
—
High $652
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| UBS | Buy | — | ↔ Maintain | 2026-07-13 |
| Truist Securities | Buy | — | ↔ Maintain | 2026-07-13 |
| RBC Capital | Outperform | — | ↔ Maintain | 2026-07-07 |
| Baird | Underperform | — | ↔ Maintain | 2026-07-07 |
| Barclays | Overweight | — | ↔ Maintain | 2026-05-06 |
| Canaccord Genuity | Hold | — | ↔ Maintain | 2026-05-05 |
| Morgan Stanley | Overweight | — | ↔ Maintain | 2026-05-05 |
| Bernstein | Outperform | — | ↔ Maintain | 2026-05-05 |
| Maxim Group | Buy | Hold → Buy | ▲ Upgrade | 2026-03-18 |
| B of A Securities | Buy | — | ↔ Maintain | 2026-03-10 |
| Citigroup | Buy | — | ↔ Maintain | 2026-03-10 |
| Oppenheimer | Outperform | — | ↔ Maintain | 2026-03-10 |
| Jefferies | Buy | — | ● Initiate | 2026-03-10 |
| HC Wainwright & Co. | Buy | — | ↔ Maintain | 2026-03-10 |
| Scotiabank | Sector Perform | — | ↔ Maintain | 2026-02-13 |
| Stifel | Hold | — | ↔ Maintain | 2026-02-13 |
| Evercore ISI Group | Outperform | — | ↔ Maintain | 2026-01-23 |
| Wolfe Research | Outperform | Peer Perform → Outperform | ▲ Upgrade | 2026-01-06 |
| Leerink Partners | Outperform | — | ↔ Maintain | 2025-12-29 |
| Wells Fargo | Overweight | — | ↔ Maintain | 2025-12-10 |
UBS
2026-07-13
Buy
↔ Maintain
Truist Securities
2026-07-13
Buy
↔ Maintain
RBC Capital
2026-07-07
Outperform
↔ Maintain
Baird
2026-07-07
Underperform
↔ Maintain
Barclays
2026-05-06
Overweight
↔ Maintain
Canaccord Genuity
2026-05-05
Hold
↔ Maintain
Morgan Stanley
2026-05-05
Overweight
↔ Maintain
Bernstein
2026-05-05
Outperform
↔ Maintain
Maxim Group
2026-03-18
Buy
(from Hold)
▲ Upgrade
B of A Securities
2026-03-10
Buy
↔ Maintain
Citigroup
2026-03-10
Buy
↔ Maintain
Oppenheimer
2026-03-10
Outperform
↔ Maintain
Jefferies
2026-03-10
Buy
● Initiate
HC Wainwright & Co.
2026-03-10
Buy
↔ Maintain
Scotiabank
2026-02-13
Sector Perform
↔ Maintain
Stifel
2026-02-13
Hold
↔ Maintain
Evercore ISI Group
2026-01-23
Outperform
↔ Maintain
Wolfe Research
2026-01-06
Outperform
(from Peer Perform)
▲ Upgrade
Leerink Partners
2025-12-29
Outperform
↔ Maintain
Wells Fargo
2025-12-10
Overweight
↔ Maintain
Profitability
Gross Margin
54.39%TTM
Op. Margin
38.13%TTM
ROE
24.20%TTM
Rev. Growth
7.80%YoY
Free Cash Flow
2.78BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
10.26MRQ
Current Ratio
3.02MRQ
Cash
7.25BMRQ
Total Debt
1.99BMRQ
Net Debt
—MRQ
How VRTX Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 122.67B |
| Enterprise Value | 117.41B |
| Trailing P/E | 29.06 |
| Forward P/E | 22.65 |
| PEG Ratio (5yr) | 1.62 |
| Price/Sales (ttm) | 10.04 |
| Price/Book (mrq) | 6.34 |
| EV/Revenue | 9.61 |
| EV/EBITDA | 23.57 |
Share Statistics
| Avg Vol (3m) | 1.55M |
| Shares Outstanding | 253.81M |
| Float | 253.04M |
| % Held by Insiders | 0.21% |
| % Held by Institutions | 97.94% |
| Short Ratio | 2.45 |
| Short % of Float | 2.22% |
Profitability
| Gross Margin | 54.39% |
| Operating Margin (ttm) | 38.13% |
| Profit Margin | 35.51% |
| Return on Assets (ttm) | 12.14% |
| Return on Equity (ttm) | 24.20% |
Income Statement
| Revenue (ttm) | 12.22B |
| Revenue Growth (yoy) | 7.80% |
| Gross Profit (ttm) | 6.65B |
| EBITDA | 4.98B |
| Net Income (ttm) | 4.34B |
| Diluted EPS (ttm) | 16.63 |
| EPS Growth (yoy) | 61.40% |
Balance Sheet
| Total Cash (mrq) | 7.25B |
| Total Debt (mrq) | 1.99B |
| Debt / Equity (mrq) | 10.26 |
| Current Ratio (mrq) | 3.02 |
| Book Value / Share | 76.18 |
| Operating CF (ttm) | 4.24B |
| Free Cash Flow (ttm) | 2.78B |
Trading & Dividends
| Beta (5Y) | 0.29 |
| 50-Day MA | 466.54 |
| 200-Day MA | 452.22 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
Ownership Breakdown
Institutional 97.94%
Insider 0.21%
Public 1.9%
Short Interest
2.22% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in VRTX in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-21 | TATSIS OURANIA | Officer | Stock Award(Grant) at price 0.00 per share. | 8,251 | — |
| 2026-07-21 | SACHDEV AMIT | Officer | Stock Award(Grant) at price 0.00 per share. | 8,251 | — |
| 2026-07-02 | MCKECHNIE DUNCAN J. | Officer | Sale at price 519.00 per share. | 1,541 | $799,779 |
| 2026-07-02 | TATSIS OURANIA | Officer | Sale at price 524.99 per share. | 1,500 | $787,485 |
| 2026-07-01 | LIU JOY | Officer | Sale at price 502.71 per share. | 828 | $416,244 |
| 2026-06-26 | BOZIC CARMEN | Officer | Sale at price 482.50 per share. | 596 | $287,570 |
| 2026-06-18 | BOZIC CARMEN | Officer | Sale at price 462.17 per share. | 1,020 | $471,413 |
| 2026-06-15 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 4,062 | $1,827,900 |
| 2026-06-05 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 1,745 | $785,250 |
| 2026-06-01 | LIU JOY | Officer | Sale at price 439.91 per share. | 828 | $364,245 |
| 2026-05-29 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 1,974 | $888,300 |
| 2026-05-15 | BUNNAGE MARK E. | Officer | Sale at price 453.45 per share. | 33 | $14,964 |
| 2026-05-15 | BOZIC CARMEN | Officer | Sale at price 453.45 per share. | 1,354 | $613,971 |
| 2026-05-12 | BOZIC CARMEN | Officer | Sale at price 450.00 per share. | 6,988 | $3,144,600 |
| 2026-05-04 | BHATIA SANGEETA N | Director | Sale at price 423.73 per share. | 318 | $134,746 |
| 2026-05-01 | LIU JOY | Officer | Sale at price 425.02 per share. | 1,104 | $469,222 |
| 2026-05-01 | MCKENZIE DIANA L | Director | Stock Award(Grant) at price 0.00 per share. | 943 | — |
| 2026-05-01 | SCHNEIDER JENNIFER J | Director | Stock Award(Grant) at price 0.00 per share. | 472 | — |
| 2026-05-01 | THORNBERRY NANCY A. | Director | Stock Award(Grant) at price 0.00 per share. | 472 | — |
| 2026-05-01 | BHATIA SANGEETA N | Director | Stock Award(Grant) at price 0.00 per share. | 943 | — |
| 2026-05-01 | GARBER ALAN M | Director | Stock Award(Grant) at price 0.00 per share. | 472 | — |
| 2026-04-01 | LIU JOY | Officer | Sale at price 449.17 per share. | 978 | $439,288 |
| 2026-03-27 | BOZIC CARMEN | Officer | Sale at price 450.95 per share. | 2,329 | $1,050,263 |
| 2026-03-13 | BOZIC CARMEN | Officer | Sale at price 481.79 per share. | 2,329 | $1,122,089 |
| 2026-03-11 | MCKECHNIE DUNCAN J. | Officer | Sale at price 498.42 per share. | 2,633 | $1,312,340 |
TATSIS OURANIA
Officer
Stock Award(Grant) at price 0.00 per share.
2026-07-21
8,251 sh
—
SACHDEV AMIT
Officer
Stock Award(Grant) at price 0.00 per share.
2026-07-21
8,251 sh
—
MCKECHNIE DUNCAN J.
Officer
Sale at price 519.00 per share.
2026-07-02
1,541 sh
$799,779
TATSIS OURANIA
Officer
Sale at price 524.99 per share.
2026-07-02
1,500 sh
$787,485
LIU JOY
Officer
Sale at price 502.71 per share.
2026-07-01
828 sh
$416,244
BOZIC CARMEN
Officer
Sale at price 482.50 per share.
2026-06-26
596 sh
$287,570
BOZIC CARMEN
Officer
Sale at price 462.17 per share.
2026-06-18
1,020 sh
$471,413
BOZIC CARMEN
Officer
Sale at price 450.00 per share.
2026-06-15
4,062 sh
$1,827,900
BOZIC CARMEN
Officer
Sale at price 450.00 per share.
2026-06-05
1,745 sh
$785,250
LIU JOY
Officer
Sale at price 439.91 per share.
2026-06-01
828 sh
$364,245
BOZIC CARMEN
Officer
Sale at price 450.00 per share.
2026-05-29
1,974 sh
$888,300
BUNNAGE MARK E.
Officer
Sale at price 453.45 per share.
2026-05-15
33 sh
$14,964
BOZIC CARMEN
Officer
Sale at price 453.45 per share.
2026-05-15
1,354 sh
$613,971
BOZIC CARMEN
Officer
Sale at price 450.00 per share.
2026-05-12
6,988 sh
$3,144,600
BHATIA SANGEETA N
Director
Sale at price 423.73 per share.
2026-05-04
318 sh
$134,746
LIU JOY
Officer
Sale at price 425.02 per share.
2026-05-01
1,104 sh
$469,222
MCKENZIE DIANA L
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-01
943 sh
—
SCHNEIDER JENNIFER J
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-01
472 sh
—
THORNBERRY NANCY A.
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-01
472 sh
—
BHATIA SANGEETA N
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-01
943 sh
—
GARBER ALAN M
Director
Stock Award(Grant) at price 0.00 per share.
2026-05-01
472 sh
—
LIU JOY
Officer
Sale at price 449.17 per share.
2026-04-01
978 sh
$439,288
BOZIC CARMEN
Officer
Sale at price 450.95 per share.
2026-03-27
2,329 sh
$1,050,263
BOZIC CARMEN
Officer
Sale at price 481.79 per share.
2026-03-13
2,329 sh
$1,122,089
MCKECHNIE DUNCAN J.
Officer
Sale at price 498.42 per share.
2026-03-11
2,633 sh
$1,312,340